{"name":"Otsuka Pharmaceutical Development & Commercialization, Inc.","slug":"otsuka-pharmaceutical-development-commercialization-inc","ticker":"","exchange":"","domain":"otsukadevelopmentcommercialization.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":20,"colorKey":"oncology","drugs":[{"name":"Abilify MyCite®","genericName":"Abilify MyCite®","slug":"abilify-mycite","indication":"Schizophrenia","status":"marketed"},{"name":"OPC-34712","genericName":"OPC-34712","slug":"opc-34712","indication":"Major depressive disorder","status":"phase_3"},{"name":"SEP-363856","genericName":"SEP-363856","slug":"sep-363856","indication":"Schizophrenia","status":"phase_3"},{"name":"AVP-786-18","genericName":"AVP-786-18","slug":"avp-786-18","indication":"Agitation associated with Alzheimer's disease dementia","status":"phase_3"},{"name":"AVP-786-28","genericName":"AVP-786-28","slug":"avp-786-28","indication":"Agitation associated with Alzheimer's disease dementia","status":"phase_3"},{"name":"AVP-786-42.63","genericName":"AVP-786-42.63","slug":"avp-786-42-63","indication":"Agitation associated with Alzheimer's disease dementia","status":"phase_3"},{"name":"Aripiprazole (BMS-337039)","genericName":"Aripiprazole (BMS-337039)","slug":"aripiprazole-bms-337039","indication":"Schizophrenia","status":"phase_3"},{"name":"Aripiprazole or other oral antipsychotics","genericName":"Aripiprazole or other oral antipsychotics","slug":"aripiprazole-or-other-oral-antipsychotics","indication":"Schizophrenia","status":"marketed"},{"name":"Brexpiprazole (OPC-34712)","genericName":"Brexpiprazole (OPC-34712)","slug":"brexpiprazole-opc-34712","indication":"Schizophrenia","status":"phase_3"},{"name":"Brexpiprazole +ADT","genericName":"Brexpiprazole +ADT","slug":"brexpiprazole-adt","indication":"Adjunctive treatment of major depressive disorder in adults with inadequate response to antidepressant monotherapy","status":"phase_3"},{"name":"Centanafadine SR","genericName":"Centanafadine SR","slug":"centanafadine-sr","indication":"Attention-deficit/hyperactivity disorder (ADHD)","status":"phase_3"},{"name":"Lamotrigine + Aripiprazole","genericName":"Lamotrigine + Aripiprazole","slug":"lamotrigine-aripiprazole","indication":"Bipolar I disorder maintenance treatment","status":"marketed"},{"name":"Lithium or Valproate with Aripiprazole","genericName":"Lithium or Valproate with Aripiprazole","slug":"lithium-or-valproate-with-aripiprazole","indication":"Bipolar I disorder, acute manic or mixed episodes","status":"marketed"},{"name":"OBR","genericName":"OBR","slug":"obr","indication":"Schizophrenia (maintenance treatment)","status":"marketed"},{"name":"OPC-34712 [Brexpiprazole] High Dose","genericName":"OPC-34712 [Brexpiprazole] High Dose","slug":"opc-34712-brexpiprazole-high-dose","indication":"Schizophrenia","status":"phase_3"},{"name":"OPC-6535 Tablets (drug)","genericName":"OPC-6535 Tablets (drug)","slug":"opc-6535-tablets-drug","indication":"Neuropathic pain","status":"phase_3"},{"name":"Olanzapine or Quetiapine or Risperidone","genericName":"Olanzapine or Quetiapine or Risperidone","slug":"olanzapine-or-quetiapine-or-risperidone","indication":"Schizophrenia","status":"phase_3"},{"name":"Paroxetine CR","genericName":"Paroxetine CR","slug":"paroxetine-cr","indication":"Major depressive disorder","status":"marketed"},{"name":"Quetiapine or Risperidone + Aripiprazole","genericName":"Quetiapine or Risperidone + Aripiprazole","slug":"quetiapine-or-risperidone-aripiprazole","indication":"Schizophrenia","status":"marketed"},{"name":"SEP363856","genericName":"SEP363856","slug":"sep363856","indication":"Schizophrenia","status":"phase_3"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":11,"colorKey":"respiratory","drugs":[{"name":"14C-SEP-380135","genericName":"14C-SEP-380135","slug":"14c-sep-380135","indication":"Other","status":"phase_1"},{"name":"Aripiprazole IM Depot","genericName":"Aripiprazole IM Depot","slug":"aripiprazole-im-depot","indication":"Other","status":"phase_3"},{"name":"Aripiprazole depot 25 or 50 mg","genericName":"Aripiprazole depot 25 or 50 mg","slug":"aripiprazole-depot-25-or-50-mg","indication":"Other","status":"phase_3"},{"name":"BPaQ","genericName":"BPaQ","slug":"bpaq","indication":"Other","status":"phase_3"},{"name":"Placebo + OBR","genericName":"Placebo + OBR","slug":"placebo-obr","indication":"Other","status":"phase_3"},{"name":"Placebo Tablet: BID","genericName":"Placebo Tablet: BID","slug":"placebo-tablet-bid","indication":"Control arm in phase 3 clinical trial (specific indication unknown)","status":"phase_3"},{"name":"Placebo depot","genericName":"Placebo depot","slug":"placebo-depot","indication":"Other","status":"phase_3"},{"name":"Quetiapine Formulation B 300mg","genericName":"Quetiapine Formulation B 300mg","slug":"quetiapine-formulation-b-300mg","indication":"Other","status":"phase_1"},{"name":"Repinatrabit","genericName":"Repinatrabit","slug":"repinatrabit","indication":"Other","status":"phase_1"},{"name":"Seroquel IR 25mg","genericName":"Seroquel IR 25mg","slug":"seroquel-ir-25mg","indication":"Other","status":"phase_1"},{"name":"Stimulant Therapy","genericName":"Stimulant Therapy","slug":"stimulant-therapy","indication":"Other","status":"marketed"}]},{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"immunology","drugs":[{"name":"Delamanid + OBR","genericName":"Delamanid + OBR","slug":"delamanid-obr","indication":"Drug-resistant tuberculosis (MDR-TB and XDR-TB) in combination with optimized background regimen","status":"phase_3"},{"name":"BPaL","genericName":"BPaL","slug":"bpal","indication":"Multidrug-resistant tuberculosis (MDR-TB)","status":"phase_3"},{"name":"BPaQM","genericName":"BPaQM","slug":"bpaqm","indication":"Malaria (uncomplicated and severe)","status":"phase_3"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"infectious","drugs":[{"name":"Placebo + ADT","genericName":"Placebo + ADT","slug":"placebo-adt","indication":"Prostate cancer","status":"phase_3"},{"name":"Aripiprazole+ ADT","genericName":"Aripiprazole+ ADT","slug":"aripiprazole-adt","indication":"Psychiatric symptoms in patients receiving androgen deprivation therapy for prostate cancer or related conditions","status":"phase_3"},{"name":"OPC-34712 + ADT","genericName":"OPC-34712 + ADT","slug":"opc-34712-adt","indication":"Prostate cancer (in combination with androgen deprivation therapy)","status":"phase_3"}]},{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"cardiovascular","drugs":[{"name":"JNT-517 Tablet","genericName":"JNT-517 Tablet","slug":"jnt-517-tablet","indication":"Obesity or overweight with weight-related comorbidities","status":"phase_3"}]},{"name":"Dermatology","slug":"dermatology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"neuroscience","drugs":[{"name":"OPA-15406","genericName":"OPA-15406","slug":"opa-15406","indication":"Atopic dermatitis","status":"phase_3"}]}],"pipeline":[{"name":"Abilify MyCite®","genericName":"Abilify MyCite®","slug":"abilify-mycite","phase":"marketed","mechanism":"Abilify MyCite is an ingestible tablet formulation of aripiprazole, a dopamine D2 and serotonin 5-HT1A receptor partial agonist, equipped with an ingestible sensor that tracks medication adherence.","indications":["Schizophrenia","Bipolar I disorder (acute manic or mixed episodes)","Major depressive disorder (adjunctive treatment)"],"catalyst":""},{"name":"Delamanid + OBR","genericName":"Delamanid + OBR","slug":"delamanid-obr","phase":"phase_3","mechanism":"Delamanid inhibits mycobacterial cell wall synthesis by targeting mycolic acid production, while OBR (optimized background regimen) provides synergistic anti-tuberculous activity through multiple complementary mechanisms.","indications":["Drug-resistant tuberculosis (MDR-TB and XDR-TB) in combination with optimized background regimen"],"catalyst":""},{"name":"JNT-517 Tablet","genericName":"JNT-517 Tablet","slug":"jnt-517-tablet","phase":"phase_3","mechanism":"JNT-517 is a selective serotonin 5-HT2C receptor agonist that promotes weight loss by increasing satiety and reducing appetite.","indications":["Obesity or overweight with weight-related comorbidities"],"catalyst":""},{"name":"OPA-15406","genericName":"OPA-15406","slug":"opa-15406","phase":"phase_3","mechanism":"OPA-15406 is a selective JAK1 inhibitor that reduces inflammatory signaling to treat immune-mediated skin diseases.","indications":["Atopic dermatitis","Other inflammatory skin conditions"],"catalyst":""},{"name":"OPC-34712","genericName":"OPC-34712","slug":"opc-34712","phase":"phase_3","mechanism":"OPC-34712 is a selective serotonin 5-HT7 receptor antagonist that modulates serotonergic neurotransmission to treat psychiatric and neurological disorders.","indications":["Major depressive disorder","Bipolar disorder"],"catalyst":""},{"name":"Placebo + ADT","genericName":"Placebo + ADT","slug":"placebo-adt","phase":"phase_3","mechanism":"Androgen deprivation therapy (ADT) involves the use of medications to suppress the production of androgens, such as testosterone, which can fuel the growth of prostate cancer cells.","indications":["Prostate cancer"],"catalyst":""},{"name":"SEP-363856","genericName":"SEP-363856","slug":"sep-363856","phase":"phase_3","mechanism":"SEP-363856 is a trace amine-associated receptor 1 (TAAR1) agonist that modulates glutamatergic and dopaminergic neurotransmission in the brain.","indications":["Schizophrenia","Bipolar disorder (exploratory)"],"catalyst":""},{"name":"14C-SEP-380135","genericName":"14C-SEP-380135","slug":"14c-sep-380135","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AVP-786-18","genericName":"AVP-786-18","slug":"avp-786-18","phase":"phase_3","mechanism":"AVP-786 is a combination of deuterated dextromethorphan and quinidine that enhances sigma-1 receptor signaling to reduce neurological symptoms.","indications":["Agitation associated with Alzheimer's disease dementia","Potential indication in other neurodegenerative or neuropsychiatric conditions"],"catalyst":""},{"name":"AVP-786-28","genericName":"AVP-786-28","slug":"avp-786-28","phase":"phase_3","mechanism":"AVP-786 is a combination of deuterated dextromethorphan and quinidine that enhances sigma-1 receptor signaling to reduce agitation and behavioral symptoms in neurodegenerative diseases.","indications":["Agitation associated with Alzheimer's disease dementia","Agitation in other neurodegenerative diseases"],"catalyst":""},{"name":"AVP-786-42.63","genericName":"AVP-786-42.63","slug":"avp-786-42-63","phase":"phase_3","mechanism":"AVP-786 is a combination of deuterated dextromethorphan and quinidine that enhances sigma-1 receptor signaling to reduce neuroinflammation and neurodegeneration.","indications":["Agitation associated with Alzheimer's disease dementia","Dementia with Lewy bodies"],"catalyst":""},{"name":"Aripiprazole (BMS-337039)","genericName":"Aripiprazole (BMS-337039)","slug":"aripiprazole-bms-337039","phase":"phase_3","mechanism":"Aripiprazole is a partial agonist at dopamine D2 and serotonin 5-HT1A receptors that modulates dopaminergic and serotonergic neurotransmission in the brain.","indications":["Schizophrenia","Bipolar I disorder (acute manic and mixed episodes)","Major depressive disorder (adjunctive treatment)","Irritability associated with autism spectrum disorder"],"catalyst":""},{"name":"Aripiprazole IM Depot","genericName":"Aripiprazole IM Depot","slug":"aripiprazole-im-depot","phase":"phase_3","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Aripiprazole depot 25 or 50 mg","genericName":"Aripiprazole depot 25 or 50 mg","slug":"aripiprazole-depot-25-or-50-mg","phase":"phase_3","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Aripiprazole or other oral antipsychotics","genericName":"Aripiprazole or other oral antipsychotics","slug":"aripiprazole-or-other-oral-antipsychotics","phase":"marketed","mechanism":"Aripiprazole is a partial agonist at dopamine D2 and serotonin 5-HT1A receptors that modulates dopaminergic and serotonergic neurotransmission to treat psychotic and mood disorders.","indications":["Schizophrenia","Bipolar I disorder (acute manic or mixed episodes)","Major depressive disorder (adjunctive treatment)","Autism spectrum disorder (irritability)","Tourette's disorder"],"catalyst":""},{"name":"Aripiprazole+ ADT","genericName":"Aripiprazole+ ADT","slug":"aripiprazole-adt","phase":"phase_3","mechanism":"Aripiprazole is a dopamine D2/D3 receptor partial agonist combined with an androgen deprivation therapy (ADT) agent to treat psychiatric symptoms in patients undergoing hormone therapy.","indications":["Psychiatric symptoms in patients receiving androgen deprivation therapy for prostate cancer or related conditions"],"catalyst":""},{"name":"BPaL","genericName":"BPaL","slug":"bpal","phase":"phase_3","mechanism":"BPaL is a three-drug combination regimen (bedaquiline, pretomanid, and linezolid) that inhibits mycobacterial ATP synthase and protein synthesis to kill drug-resistant tuberculosis bacteria.","indications":["Multidrug-resistant tuberculosis (MDR-TB)","Extensively drug-resistant tuberculosis (XDR-TB)"],"catalyst":""},{"name":"BPaQ","genericName":"BPaQ","slug":"bpaq","phase":"phase_3","mechanism":"BPaQ is a prodrug formulation designed to improve the oral bioavailability and therapeutic delivery of its active moiety.","indications":[],"catalyst":""},{"name":"BPaQM","genericName":"BPaQM","slug":"bpaqm","phase":"phase_3","mechanism":"BPaQM is a novel antimalarial compound that acts as a blood schizonticide to prevent malaria parasite multiplication in red blood cells.","indications":["Malaria (uncomplicated and severe)"],"catalyst":""},{"name":"Brexpiprazole (OPC-34712)","genericName":"Brexpiprazole (OPC-34712)","slug":"brexpiprazole-opc-34712","phase":"phase_3","mechanism":"Brexpiprazole is a serotonin-dopamine activity modulator (SDAM) that acts as a partial agonist at dopamine D2 and serotonin 5-HT1A receptors while antagonizing serotonin 5-HT2A receptors.","indications":["Schizophrenia","Schizoaffective disorder","Major depressive disorder (adjunctive treatment)"],"catalyst":""},{"name":"Brexpiprazole +ADT","genericName":"Brexpiprazole +ADT","slug":"brexpiprazole-adt","phase":"phase_3","mechanism":"Brexpiprazole is an atypical antipsychotic that acts as a dopamine D2 receptor partial agonist and serotonin 5-HT1A receptor partial agonist, combined with adjunctive antidepressant therapy (ADT) to treat major depressive disorder.","indications":["Adjunctive treatment of major depressive disorder in adults with inadequate response to antidepressant monotherapy"],"catalyst":""},{"name":"Centanafadine SR","genericName":"Centanafadine SR","slug":"centanafadine-sr","phase":"phase_3","mechanism":"Centanafadine is a triple monoamine reuptake inhibitor that blocks the reuptake of serotonin, norepinephrine, and dopamine.","indications":["Attention-deficit/hyperactivity disorder (ADHD)"],"catalyst":""},{"name":"Lamotrigine + Aripiprazole","genericName":"Lamotrigine + Aripiprazole","slug":"lamotrigine-aripiprazole","phase":"marketed","mechanism":"Lamotrigine stabilizes neuronal membranes by blocking sodium channels, while aripiprazole acts as a dopamine D2/D3 receptor partial agonist, together modulating neurotransmission to treat mood and psychotic disorders.","indications":["Bipolar I disorder maintenance treatment","Bipolar depression"],"catalyst":""},{"name":"Lithium or Valproate with Aripiprazole","genericName":"Lithium or Valproate with Aripiprazole","slug":"lithium-or-valproate-with-aripiprazole","phase":"marketed","mechanism":"Aripiprazole acts as a dopamine D2/D3 receptor partial agonist and serotonin 5-HT1A partial agonist, while lithium and valproate modulate intracellular signaling and gene expression to enhance mood stabilization and reduce manic/depressive symptoms.","indications":["Bipolar I disorder, acute manic or mixed episodes","Bipolar disorder maintenance treatment"],"catalyst":""},{"name":"OBR","genericName":"OBR","slug":"obr","phase":"marketed","mechanism":"OBR is a long-acting injectable antipsychotic that blocks dopamine D2 receptors in the brain to treat schizophrenia and bipolar disorder.","indications":["Schizophrenia (maintenance treatment)","Bipolar I disorder (maintenance treatment)"],"catalyst":""},{"name":"OPC-34712 + ADT","genericName":"OPC-34712 + ADT","slug":"opc-34712-adt","phase":"phase_3","mechanism":"OPC-34712 is a selective serotonin 5-HT7 receptor antagonist combined with androgen deprivation therapy (ADT) to treat prostate cancer.","indications":["Prostate cancer (in combination with androgen deprivation therapy)"],"catalyst":""},{"name":"OPC-34712 [Brexpiprazole] High Dose","genericName":"OPC-34712 [Brexpiprazole] High Dose","slug":"opc-34712-brexpiprazole-high-dose","phase":"phase_3","mechanism":"Brexpiprazole is a partial agonist at serotonin 5-HT1A receptors and a partial agonist at dopamine D2 receptors.","indications":["Schizophrenia","Major depressive disorder as adjunctive therapy"],"catalyst":""},{"name":"OPC-6535 Tablets (drug)","genericName":"OPC-6535 Tablets (drug)","slug":"opc-6535-tablets-drug","phase":"phase_3","mechanism":"OPC-6535 is a selective antagonist of the P2X7 receptor, an ATP-gated ion channel involved in inflammatory and immune responses.","indications":["Neuropathic pain","Inflammatory conditions"],"catalyst":""},{"name":"Olanzapine or Quetiapine or Risperidone","genericName":"Olanzapine or Quetiapine or Risperidone","slug":"olanzapine-or-quetiapine-or-risperidone","phase":"phase_3","mechanism":"These atypical antipsychotics block dopamine D2 and serotonin 5-HT2A receptors to reduce psychotic symptoms and stabilize mood.","indications":["Schizophrenia","Bipolar I disorder (acute mania and maintenance)","Major depressive disorder (adjunctive treatment)"],"catalyst":""},{"name":"Paroxetine CR","genericName":"Paroxetine CR","slug":"paroxetine-cr","phase":"marketed","mechanism":"Paroxetine CR selectively inhibits the reuptake of serotonin at the neuronal synapse, increasing serotonin availability in the brain.","indications":["Major depressive disorder","Generalized anxiety disorder","Panic disorder","Obsessive-compulsive disorder","Post-traumatic stress disorder"],"catalyst":""},{"name":"Placebo + OBR","genericName":"Placebo + OBR","slug":"placebo-obr","phase":"phase_3","mechanism":"This is a placebo control arm combined with OBR (a comparator treatment), used in a Phase 3 clinical trial to establish efficacy and safety baselines.","indications":[],"catalyst":""},{"name":"Placebo Tablet: BID","genericName":"Placebo Tablet: BID","slug":"placebo-tablet-bid","phase":"phase_3","mechanism":"Placebo has no active pharmacological mechanism; it is an inert substance used as a control in clinical trials.","indications":["Control arm in phase 3 clinical trial (specific indication unknown)"],"catalyst":""},{"name":"Placebo depot","genericName":"Placebo depot","slug":"placebo-depot","phase":"phase_3","mechanism":"Placebo depot does not have an active pharmacological mechanism; it is used as a control in clinical trials.","indications":[],"catalyst":""},{"name":"Quetiapine Formulation B 300mg","genericName":"Quetiapine Formulation B 300mg","slug":"quetiapine-formulation-b-300mg","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Quetiapine or Risperidone + Aripiprazole","genericName":"Quetiapine or Risperidone + Aripiprazole","slug":"quetiapine-or-risperidone-aripiprazole","phase":"marketed","mechanism":"These atypical antipsychotics block dopamine and serotonin receptors in the brain to reduce psychotic symptoms and stabilize mood.","indications":["Schizophrenia","Bipolar disorder","Major depressive disorder (adjunctive treatment)","Acute agitation"],"catalyst":""},{"name":"Repinatrabit","genericName":"Repinatrabit","slug":"repinatrabit","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"SEP363856","genericName":"SEP363856","slug":"sep363856","phase":"phase_3","mechanism":"SEP363856 is a trace amine-associated receptor 1 (TAAR1) agonist that modulates glutamatergic and dopaminergic neurotransmission in the brain.","indications":["Schizophrenia","Bipolar disorder (acute mania)"],"catalyst":""},{"name":"Seroquel IR 25mg","genericName":"Seroquel IR 25mg","slug":"seroquel-ir-25mg","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Stimulant Therapy","genericName":"Stimulant Therapy","slug":"stimulant-therapy","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMif0FVX3lxTFBxVVpNR1NsUDZ4UmNUU2dnLTdGZzRWNmFhZjBWdUV2Unh0c0NsdTF3OE9ZOEkxM1N6VFlFa2xtS0N4aFJUdElOYVhGZ2prLXc1V2p3TkUzUWtWd1Z1ZHZHYVRpZHoyZnY1ZzdUcTgyTURyT21pNVdxSm1FLTVCems?oc=5","date":"2026-01-27","type":"regulatory","source":"Psychiatrist.com","summary":"FDA Fast-Tracks Otsuka’s Novel ADHD Drug - Psychiatrist.com","headline":"FDA Fast-Tracks Otsuka’s Novel ADHD Drug","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipAFBVV95cUxORnpmWGlwSXZVWXNhODh0ZWRTelFDV2hZdWZkSXk3NGxuU3ZCSkpiU2JtWFp1WDBqcWljMG1qemF1LWhEdHFCM2RnVmVaT3NpQnRJMkRJT3QwX0JzRmcwQ3hlcjV4OTVqdGZWWWZjWTNJZFNORGxqQkN0UVFxaHdiaDNKaV9vWGFsWFp0blNUT3hYTWdvLXZvSGtWQmZQXzZEZUdhVA?oc=5","date":"2026-01-27","type":"regulatory","source":"The Pharma Letter","summary":"FDA accepts Otsuka’s centanafadine NDA for priority review - The Pharma Letter","headline":"FDA accepts Otsuka’s centanafadine NDA for priority review","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1wJBVV95cUxPRWNfY2xLRHdNeVg1UXd5aktOU2JXdUpISFR4akdDN0ZiR2NEOWZrQnZkNGg1Zl9MbklMRmw2UngyWGUzVVVweFVQSk84VUQyMVZTY1ZMMFk4d2xLMzJlSXVjbm5MV090YnFQZ1hudnE5eUs3aTVWUmRnN1hORl9tRi1BTkx4YU5COG9CaXZqYnhmcEFwNm1QSGJUdkVJdkctcjZaWlNValkxcTkwdjJqTjFOb1g4NXpMcHZncy0ya29nZjJxX2loUEliV2c2cy1JZGJSTmVMVDNTQlBPSGRiVXUxcF9iX2J6b1R1a1JQOVBzYkZQQThMQm04SlFQQjl3S2RMekFyRENnRTlUMlQzdWZfWXpHbzJfXzVJa04xNERhRHU4eVlxSnl2a2taWGNjYWtJaFlIV2lOdnZTeVhaRmdlWXBGaHNPSDFRczNwc2xsRndBX0lB?oc=5","date":"2025-12-15","type":"regulatory","source":"Business Wire","summary":"GENESIS Pharma announces a new partnership with Otsuka Pharmaceutical Europe Ltd. for the commercialization of donidalorsen for hereditary angioedema in Central and Eastern Europe - Business Wire","headline":"GENESIS Pharma announces a new partnership with Otsuka Pharmaceutical Europe Ltd. for the commercialization of donidalor","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwgFBVV95cUxNNmJ2MHZuMl9qRElZU3VxTnJlQWRHMXNoM2tWajlMeTlqU3N5RXFLX29kTURyalViREduQzNWRU4yNjVoZUo5Zi1wM0FvSTl3STRyM3Nld01tLVJ5YXFXN0tiOGtJQWxTSnJyQVZKbF9VLVAweWFIeDdOTm1uZjEtMGJJV0dNdFdqQWl3RnVvb0hPWllELU5aS1VPbEd6R1psMGItMVRlam9tTFo5VmM2UW9lR1dUYkNLUUFfcHF1M0hvdw?oc=5","date":"2025-11-25","type":"regulatory","source":"Patient Care Online","summary":"Otsuka Submits NDA to FDA for Centanafadine for Treatment of ADHD Across the Lifespan - Patient Care Online","headline":"Otsuka Submits NDA to FDA for Centanafadine for Treatment of ADHD Across the Lifespan","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwFBVV95cUxOM0Rmb05BQkF4VVVHY0RyNXZGZnRFVHpyREZpQnVoVjlNZkhHeEpnTTZIcTk2bm8xVWVrdWVSc29Fa2s3VjlDVG5XZndVS3lKTURiZ2xmU1c0SGgwVkNKSEJUamNPdHJQZ3d0ZVgza3QtdVk3YnBBTW1UdGJRR1pPV1ktV1NUQkV4eXZtSXg1VkNtWHVudjRLR1lxV1ZOSEk?oc=5","date":"2025-07-16","type":"deal","source":"Fierce Biotech","summary":"Otsuka inks $613M deal for Swedish biotech's IL1RAP antibodies - Fierce Biotech","headline":"Otsuka inks $613M deal for Swedish biotech's IL1RAP antibodies","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiswJBVV95cUxPNjN2UWozM0I4MGFkdzl5M1JaZ2VnVWpscklDVmdHd29mQjZ1VWxaSGNmWTdqNHR2WWZfUm5GdF9iUm5rVEt2UUJMTGo3ci1OcFZRdDZkcDA5YjNuYmx2MnRWYUFzRVEzdGVoMzBpRFZjRE9uVGlQVmZQTHNQQkRRQ3pKMTV6S25WSWtzbDFPUGRjc0gweGM4UVItSUp0ZVlUZ3VQR3BJSTY4QkVjNHIzc2FjWEZOX2pqMmNYNENNY0lQeVk0UHhucGhGeFR1LVFtME9aZk5ybmdZVG9adE10dmpScFBjNTBGVlhsd2JyaTdvV25UNVV5WTJpX19ROTZDUnhyMFdIZlRmWHlKLWJsVTJ4U0pzWjk4YmtENlRZRDRqMTVjRUJmLW56cFlOdmNlZWRV?oc=5","date":"2025-06-06","type":"trial","source":"BioSpace","summary":"Otsuka Sibeprenlimab Phase 3 Data Show a Statistically Significant and Clinically Meaningful Proteinuria Reduction for the Treatment of Immunoglobulin A Nephropathy (IgAN) - BioSpace","headline":"Otsuka Sibeprenlimab Phase 3 Data Show a Statistically Significant and Clinically Meaningful Proteinuria Reduction for t","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxNRi1iQjhUMDg4UHFySzZMUWwzUXFmT3VvYXpFamR4SkNMWnA4ZHo3azZzbkV6cjVOYkhlTGt6VmhTUmNyWWxORHJSYk5famwxSUtaN3VVeE5wNTZaNVNoUHdVM2xCVXQzM0tEMDFfQ2hBaS14WXMtQkZDYWJfVzkwV0M0SWhORk5PY1YzRmtWOFBrNE5NVUxJ?oc=5","date":"2024-10-29","type":"pipeline","source":"New Jersey Business & Industry Association","summary":"Otsuka Funds Grants to Address Mental Health Inequities in NJ Communities - New Jersey Business & Industry Association","headline":"Otsuka Funds Grants to Address Mental Health Inequities in NJ Communities - New Jersey Business & Industry Association","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMid0FVX3lxTE15OEdUNEQ0UWdzeEtTcU9lU3NrM2gzdlMtWUdxMmd0b1VVYmM3d1Mxc21uNW9MM2tlVVdISExla3lubVpuRms2ZUljVkh2VlkwTGtySUVSaWhuRHY5N21fTkpqMmw1b3BEbGlrYWNiVHU3TVhqcDF3?oc=5","date":"2024-05-30","type":"pipeline","source":"Life Science Leader","summary":"Where Are They Now? Otsuka - Life Science Leader","headline":"Where Are They Now? Otsuka","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilgFBVV95cUxNMzlDdTFTN0NZRHpyUFpJRmxsQnIwMFlZenBxVUJ1SWpEd0ltSUx3SWZVeEZfZlZPWmU1MDJEODlqS1ppeVN5eGFQLVJfRTFRMWhPVmZyc1ZXZGpiZVRHTmZLX2V1SmNhX0dBV0xjQXJpWl9wLXZWUUZTblZMUHNBTVlOQWFyWWdiWld4TXFtWmNjQ3I0VVE?oc=5","date":"2023-08-31","type":"deal","source":"newsfilecorp.com","summary":"Otsuka Pharmaceutical to Acquire Mindset Pharma - newsfilecorp.com","headline":"Otsuka Pharmaceutical to Acquire Mindset Pharma","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwFBVV95cUxOTXViSXRzZm1hODRaakNqZkhxZnNHalMzTk9MNVBvRGZGTk5zbm1vX3BGdDI3RmhUNGN1T3AxY1FiZjMyYi1jWDR4cVFkVFRqdEhYNmt0OU04S0dkbWRLZGJvUktVYTBvaEd1S3ZGTFl2dUJNczRjT0h1eFhvUDFja09IdkFTLVBNdUlj?oc=5","date":"2020-01-14","type":"deal","source":"statnews.com","summary":"A forerunner in ‘smart pills’ adopts a new tack as key pharma partnership unravels - statnews.com","headline":"A forerunner in ‘smart pills’ adopts a new tack as key pharma partnership unravels","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigwFBVV95cUxPNEtWb1hOd0VnMkNPTXd3Z3JieEo0aU1TNXV3VG9PNVUxdGtYSjVqclo5RkM4UERVX0lQVFYzZjVROWJqendfYkw4ZDl6aFRyUXhGWjRQa3BUQm5SUnFoUzI3ckdjN0pENl8tcTd5S2pNVlk3b25Wc2p5bnhVcm1QQ20xWQ?oc=5","date":"2019-08-20","type":"pipeline","source":"Binghamton University","summary":"Two summer interns learn the ropes - Binghamton University","headline":"Two summer interns learn the ropes","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimAFBVV95cUxNQUZBLWM2ZUFhUzUxdkxwVTlPbGZTamh4amowemRibmRCZmtxa3NuTTB4ZzdQTXVFTFpYdFFJRlFHdTh5clA3TmZuR2ZSUUJoa2Y5TVpOcGdkOHNLVjN2cWlxLXk5N09XVHpZZ1B6dGtKTnlhUGg5TVlveUptRnp6bmxMZ3dyN2t0eGFISThmdFhZMDNNc2pSaw?oc=5","date":"2019-01-29","type":"trial","source":"Clinical Leader","summary":"Otsuka: Real-Time Data Changes Trial Paradigm - Clinical Leader","headline":"Otsuka: Real-Time Data Changes Trial Paradigm","sentiment":"neutral"}],"patents":[],"drugCount":39,"phaseCounts":{"marketed":8,"phase_3":27,"phase_1":4},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}